In prolactinomas, dopamine agonist suppressed hormone release and tumour shrinkage, but such an effect in clinically NFPA is disputed despite the comparable distribution of mRNA for D2R in NFPA [330]. The gene discussed is DRD2; the disease is neoplasm.